[go: up one dir, main page]

WO2004094462A3 - Methods of peptide preparation - Google Patents

Methods of peptide preparation Download PDF

Info

Publication number
WO2004094462A3
WO2004094462A3 PCT/GB2004/001791 GB2004001791W WO2004094462A3 WO 2004094462 A3 WO2004094462 A3 WO 2004094462A3 GB 2004001791 W GB2004001791 W GB 2004001791W WO 2004094462 A3 WO2004094462 A3 WO 2004094462A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
amino acids
sector
cationic
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2004/001791
Other languages
French (fr)
Other versions
WO2004094462A2 (en
Inventor
Oeystein Rekdal
John Sigurd Svendsen
Mari Wikman
Terese Solstad
Nannan Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lytix Biopharma AS
Original Assignee
Lytix Biopharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lytix Biopharma AS filed Critical Lytix Biopharma AS
Publication of WO2004094462A2 publication Critical patent/WO2004094462A2/en
Publication of WO2004094462A3 publication Critical patent/WO2004094462A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a method of producing a bioactive peptide, wherein said peptide is 4 to 25 amino acids in length, has at least 2 cationic amino acids and is capable of forming an amphipathic helical structure, which method comprises identification of a cationic sector and division of the remaining part of the peptide into three further sectors which are substantially equal in size, and incorporation of at least 65 % of the bulk and lipophilicity provided by the amino acids R groups into the sector flanking the right side of the cationic sector; and to uses of the peptides produced thereby in therapy, particularly in the treatment of benign or malignant tumours.
PCT/GB2004/001791 2003-04-23 2004-04-23 Methods of peptide preparation Ceased WO2004094462A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20031818A NO20031818D0 (en) 2003-04-23 2003-04-23 Process of bioactive peptide preparation
NO20031818 2003-04-23

Publications (2)

Publication Number Publication Date
WO2004094462A2 WO2004094462A2 (en) 2004-11-04
WO2004094462A3 true WO2004094462A3 (en) 2005-02-10

Family

ID=19914696

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/001791 Ceased WO2004094462A2 (en) 2003-04-23 2004-04-23 Methods of peptide preparation

Country Status (2)

Country Link
NO (1) NO20031818D0 (en)
WO (1) WO2004094462A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2252627T3 (en) 2008-01-24 2017-08-14 Esperance Pharmaceuticals MERGER CONSTRUCTION WITH LYTIC DOMAIN AND METHOD FOR PRODUCING AND USING SAME.
US9492563B2 (en) 2012-10-30 2016-11-15 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use
TWI577697B (en) * 2013-11-28 2017-04-11 國立清華大學 Salt and protease-resistance of antimicrobial peptide and the manufacture thereof
GB201401877D0 (en) * 2014-02-04 2014-03-19 Univ Tromsoe Peptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012541A2 (en) * 1998-08-28 2000-03-09 Alpharma As Cytotoxic peptides modified by bulky or lipophilic moieties
WO2001019852A2 (en) * 1999-08-31 2001-03-22 Alpharma As Methods of peptide preparation
WO2001066147A2 (en) * 2000-03-09 2001-09-13 Alpharma As Antimicrobial compounds and formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012541A2 (en) * 1998-08-28 2000-03-09 Alpharma As Cytotoxic peptides modified by bulky or lipophilic moieties
WO2001019852A2 (en) * 1999-08-31 2001-03-22 Alpharma As Methods of peptide preparation
WO2001066147A2 (en) * 2000-03-09 2001-09-13 Alpharma As Antimicrobial compounds and formulations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JONG EUN OH ET AL: "SYNTHESIS OF NOVEL UNNATURAL AMINO ACID AS A BUILDING BLOCK AND ITSINCORPORATION INTO AN ANTIMICROBIAL PEPTIDE", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 7, no. 12, 1999, pages 2985 - 2990, XP001053315, ISSN: 0968-0896 *
PUYAL C ET AL: "DESIGN OF A SHORT MEMBRANE-DESTABILIZING PEPTIDE COVALENTLY BOUND TO LIPOSOMES", BIOCHIMICA ET BIOPHYSICA ACTA, AMSTERDAM, NL, vol. 1195, no. 2, 1994, pages 259 - 266, XP001053363, ISSN: 0006-3002 *

Also Published As

Publication number Publication date
WO2004094462A2 (en) 2004-11-04
NO20031818D0 (en) 2003-04-23

Similar Documents

Publication Publication Date Title
CY1109450T1 (en) METHODS OF MANUFACTURING PEPTIDES
WO2000049040A3 (en) Antimicrobial/endotoxin neutralizing polypeptide
WO2003037932A3 (en) Human coagulation factor vii polypeptides
AU2002303214A1 (en) Lps-responsive chs1/beige-like anchor gene and therapeutic applications thereof
WO2004094462A3 (en) Methods of peptide preparation
WO2002094859A3 (en) Mage-a1 peptides for treating or preventing cancer
IL207012A (en) Pharmaceutical composition comprising sgp28 and a vaccine composition for the treatment of a cancer expressing sgp28
AU5992500A (en) Compound derived from an offset orf of the ice gene
WO2001088084A3 (en) A novel polypeptide, a superoxide dismutase 11 and the polynucleotide encoding the polypeptide
WO2001075048A3 (en) A novel polypeptide, human ribosomal protein s11 23 and the polynucleotide encoding the polypeptide
WO2001075002A3 (en) A novel polypeptide, cellular cycle regulation gene 28 and the polynucleotide encoding the polypeptide
WO2001075057A3 (en) A novel polypeptide, human ribosomal s4 protein 12 and the polynucleotide encoding the polypeptide
WO2001096526A3 (en) A novel polypeptide, a human tumor suppressor factor 11.77 and the polynucleotide encoding the polypeptide
WO2004089980A3 (en) Therapeutic cancer vaccine
WO2001075046A3 (en) A novel polypeptide, mitotic cycle human regulation gene 17 and the polynucleotide encoding the polypeptide
WO2001075011A3 (en) A novel polypeptide, cytochrome human constitution protein 10 and the polynucleotide encoding the polypeptide
WO2002008421A1 (en) A novel polypeptide, a human tumor necrosis factor receptor 21.45 and the polynucleotide encoding the polypeptide
WO2001064866A1 (en) A novel polypeptide, a ribosome s19e protein 11 and the polynucleotide encoding the polypeptide
WO2001075028A3 (en) A novel polypeptide, human ribosomal protein s4-12 and the polynucleotide encoding the polypeptide
WO2001075018A3 (en) A novel polypeptide, a human regulation factor of transcription 31 and the polynucleotide encoding the polypeptide
WO2001083682A3 (en) A novel polypeptide, a human pax protein 11.6 and the polynucleotide encoding the polypeptide
WO2001075012A3 (en) A novel polypeptide, human signal peptide 10 of a lipoprotein precursor protein and the polynucleotide encoding the polypeptide
WO2001083681A3 (en) A novel polypeptide, a human dihydroorotase 21 and the polynucleotide encoding the polypeptide
WO2001075007A3 (en) A novel polypeptide, a tyrosinase 15 and the polynucleotide encoding the polypeptide
WO2001075056A3 (en) A novel polypeptide, human light-chain clathrine 20 and the polynucleotide encoding the polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase